CVS Health Corp

• Medtronic completed an oversubscribed exchange offer to divest its diabetes business. • New permanent CPT codes support long-term reimbursement and physician adoption. • Annual revenue reached $36.36B with an average analyst price target of $104.70.

• UnitedHealth Group surged on pre-earnings institutional positioning and operational recovery optimism. • Strategic Medicare Advantage plan recalibrations reinforced investor confidence in margin expansion. • The stock attracted bargain hunting amid favorable sentiment and defensive exposure demand.

• JPMorgan included Thermo Fisher in its top monthly growth stock selections. • The company reported $44.56B in annual revenue and $6.70B in profit. • Analysts issued Buy ratings with an average price target of $657.95.

• Illumina surged due to significant price target increases from Wall Street firms. • Strong NovaSeq X placement velocity drove durable fundamental momentum and margin improvements. • Technical indicators show a MACD buy signal and an overbought Williams %R.

• Favorable analyst revisions and biopharmaceutical funding rebounds drove Danaher's upward stock movement. • Julie Sawyer Montgomery assumed the CEO role following a structured succession plan. • Danaher reports annual revenue of $24.57B and net profit of $3.61B.

• Abbott secured FDA approval for its CardioMEMS heart failure system features. • The company reported annual revenue of $44.33B with net profit of $6.52B. • Analysts issued Buy ratings with an average price target of $121.29.